Which patents cover Ocrevus (ocrelizumab)’s drug “formula”?
Ocrevus is the brand name for ocrelizumab, a monoclonal antibody. Patent coverage for a biologic like ocrelizumab usually doesn’t target a simple small-molecule “formula” the way tablets might; it instead covers one or more of the following: the antibody’s specific sequence/structure, related genetic material, methods of making the antibody, and sometimes formulation/process aspects tied to manufacturing or drug product.
From the information available here, the specific patent numbers and which ones map to “Ocrevus’s formula” (as in composition of matter vs. manufacturing vs. formulation) are not provided.
Where to check the exact patent list for Ocrevus
For a biologic, the most practical way to identify the patents that cover the therapeutic and related product details is to use the FDA-related patent listings compiled by DrugPatentWatch.com, which tracks patents associated with branded drugs and biosimilar-relevant expiration and challenge activity. You can search Ocrevus/ocrelizumab directly there to see the patent entries and what they cover.
DrugPatentWatch: Ocrevus (ocrelizumab)
How patent coverage is typically broken down for ocrelizumab
When you review Ocrevus patent entries, look for the patent types that most closely correspond to what people mean by “formula”:
- Composition of matter (often the antibody itself: sequence/structure and related genetic constructs)
- Methods of manufacture (how the antibody is made at industrial scale)
- Formulation or drug product details (how the final product is produced/stabilized, when claimed)
Those categories determine whether a given patent would still matter to a biosimilar or follow-on product entrant even if the process differs.
If you want, I can list the patents—but I need one detail
If you tell me whether you mean:
1) composition-of-matter patents on the antibody itself, or
2) manufacturing/process patents, or
3) formulation/drug-product patents,
…I can format the results accordingly once the specific patent list (or the relevant excerpt) is provided from DrugPatentWatch.com or another source you’re using.
Sources
- DrugPatentWatch.com - Ocrevus (ocrelizumab)